NASDAQ · CTSO
Healthcare · Medical - Devices
$4.56
Up+$0.02 (+0.44%)
Updated Nov 5, 2026, 4:21 AM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CTSO
1M range · 0 trading sessions · Daily adjusted prices
CTSO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CTSO.
Company
Market Activity
Research & News
CTSO research
Company profile and research snapshot.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 21, 2026 | WBB Securities | Speculative Buy | — |
| Mar 26, 2026 | D. Boral Capital | Buy | — |
| Jan 12, 2026 | D. Boral Capital | Buy | — |
| Dec 16, 2025 | D. Boral Capital | Buy | — |
| Nov 14, 2025 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 29, 2026
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2026 financial results and recent business highlights after the market close on Thursday, November 12, 2026.
Benzinga · Oct 21, 2026
WBB Securities analyst Karen Sterling initiates coverage on CytoSorbents (NASDAQ:CTSO) with a Speculative Buy rating and announces Price Target of $9.5.
Yahoo · Sep 30, 2026
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart surgery at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain from October 7-10, 2026 and in critical care at the European Society of Intensive Care Medicine (ESICM) Annual Congress in Lisbon, Portugal from October 1
Yahoo · Sep 23, 2026
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has regained compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTSO.
